Intraocular Lenses Industry Market Size, Share - Growth Analysis Report and Forecast Trends 2026-2030

Intraocular lenses are medical devices implanted inside the eye to replace the eye's natural lens, most commonly during cataract surgery but also for refractive correction in presbyopic and myopic patients. The global market was valued at approximately $4.6 billion in 2023 and is on track to reach roughly $6.8 billion by 2030, reflecting a compound annual growth rate of 5.7%. With over 20 million IOL implants performed annually worldwide, the market benefits from a vast and recurring procedural base driven primarily by cataract incidence and elective refractive surgery demand.

• •Over 20 million IOL implants are performed globally each year, predominantly during cataract extraction procedures
• •The broader ocular implant market, which encompasses IOLs among other products, was valued at $15.72 billion in 2024 and is expanding at roughly 5.8% annually through 2030
• •Traditional monofocal IOLs represent the largest volume segment, though premium and specialty IOLs are growing at a faster rate

The single largest driver is demographic: populations worldwide are aging, and cataract prevalence rises sharply with age, sustaining robust procedural volumes. Rising disposable income and patient expectations in emerging and developed markets alike are accelerating demand for premium IOLs that address presbyopia, astigmatism, and other refractive errors in a single procedure. Additionally, the global burden of presbyopia is projected to reach 2.1 billion people by 2030, expanding the candidate pool for refractive IOL solutions including phakic intraocular lenses.

• •Premium IOL revenue is projected to grow at a 9.03% CAGR from 2021 to 2028, significantly outpacing traditional monofocal IOL growth at 6.2%
• •Phakic IOL implantation volumes are expanding at approximately 9.6% annually as a refractive alternative for high myopia and presbyopia correction
• •Government statistical agencies track procedural volumes and expenditure codes for IOL insertions, confirming the large-scale and well-documented nature of the underlying clinical demand

The IOL market is broadly segmented into monofocal, multifocal, extended depth-of-focus (EDOF), accommodative, and phakic lenses, with premium categories (multifocal, EDOF, and toric) capturing disproportionate share of revenue growth. Geographically, North America and Europe dominate in terms of premium IOL adoption rates due to favorable reimbursement landscapes and higher patient awareness, while Asia-Pacific represents the fastest-growing region owing to expanding healthcare infrastructure and rising cataract surgical volumes. Latin America and the Middle East are also emerging markets as surgical capacity and access improve.

• •Premium IOLs (multifocal, EDOF, toric) are gaining share as patients seek spectacle independence following cataract or refractive surgery
• •Asia-Pacific is the fastest-growing regional market, driven by aging demographics and rapid expansion of ophthalmic surgical infrastructure
• •Phakic IOLs, used in refractive surgery for patients unsuitable for laser vision correction, are seeing accelerated adoption globally

What are the recent trends and outlook?

Looking forward, the IOL market is expected to continue its steady expansion, with premium and refractive IOLs representing an increasing share of the overall value pool. Miniaturization of incision techniques, integration of drug-delivery capabilities, and the development of smart or adjustable IOL platforms are emerging areas of innovation. As presbyopia and cataract burdens grow and patient expectations for spectacle-free vision rise, the trajectory favors sustained above-market growth for premium IOL categories through the end of the decade.

• •The global IOL market is projected to approach $6.8 billion by 2030, maintaining approximately 5.7% annual growth through the forecast horizon
• •Extended depth-of-focus and trifocal premium IOL designs are expected to capture increasing surgeon and patient preference over conventional multifocal platforms
• •Phakic IOL adoption will continue expanding, supported by rising myopia prevalence and growing suitability among patients ineligible for corneal refractive surgery